TABLE 2.

VTE in CIA by primary malignancy

	No Treatment	RBC only	ESA only	RBC and ESA	Total Patients
Lung	164/ (471) = 34.8%	35 /(97) = 36.1%	8 / (28) = 28.6%	1 /(16) = 6.3%	208 /(612) = 34.0%
		HR = 1.19, 95% CI 0.83‐1.71, P = .34	HR = 0.52, 95% CI 0.26‐1.01, P = .34
Soft Tissue	126 /(185) = 68.1%	18 / (46) = 39.1%	10 /(14) = 71.4%	4 / (18) = 22.2%	158/(263) = 60.1%
		HR = 0.40, 95% CI 0.25‐0.63, P < .001	HR = 0.73, 95% CI 0.42‐1.27, P = .26
Colon	48 /(233) = 20.6%	9 /(29) = 31.0%	0 / (9) = 0.0%	1 /(3) = 33.3%	58/(274) = 21.2%
		HR = 2.40, 95% CI 1.21‐4.75, P = .012	HR = 0.38, 95% CI 0.05‐2.72, P = .33
Gastric	51 /(207) = 24.6%	13 /(47) = 27.7%	1 /(11) = 9.1%	0 /(1) = 0.0%	65 /(266) = 24.4%
		HR = 1.78, 95% CI 0.97‐3.28, P = .06	HR = 0.36, 95% CI 0.05‐2.58, P = .31
Biliary	7 / (45) = 15.6%	1 / (6) = 16.7%	2 /(4) = 50.0%	0 /(1) = 0.0%	10 / (56) = 17.9%
		HR = 1.11, 95% CI 0.14‐8.78, P = .92	HR = 4.58, 95% CI 0.97‐21.61
Breast	64 /(347) = 18.4%	6 /(36) = 16.7%	1 /(14) = 7.1%	1 / (2) = 50.0%	72/(399) = 18.0%
		HR = 1.41, 95% CI 0.65‐3.07, P = .39	HR = 0.67, 95% CI 0.16‐2.72, P = .57
Bone Marrow	367 /(887) = 41.4%	136 / (311) = 43.7%	8 / (21) = 38.1%	1 /(11) = 9.1%	512/(1230) = 41.6%
		HR = 1.36, 95% CI 1.12‐1.66, P = .002	HR = 0.65, 95% CI 0.34‐1.26, P = .20
Head and Neck	33 /(213) = 15.5%	12 /(39) = 30.8%	2 /(4) = 50.0%	0/ (2) = 0.0%	47/(258) = 18.2%
		HR = 2.47, 95% CI 1.27‐4.80, P = .008	HR = 2.75, 95% CI 0.66‐11.54, P = .17
Genitourinary	50 /(157) = 31.8%	10 /(23) = 43.5%	2 / (3) = 66.7%	1 /(3) = 33.3%	63/(186) = 33.9%
		HR = 1.80, 95% CI 0.93‐3.49, P = .08	HR = 1.30, 95% CI 0.40‐4.26, P = .66

Note: In the above table, each value listed as (x/y), x pertains to all patients who received the specified treatment who had a VTE, while y pertains to all patients who received the specified treatment.